רווח תפעולי לפני פחת: acrivon.com (ACRV)
Why does Acrivon Therapeutics (ACRV) command such deep confidence from scientists and investors? Acrivon Therapeutics is developing precision oncology for the B2B sector, utilizing protein profiles to predict patient response. This ensures success where conventional methods fail. The EBITDA trend confirms financial stability, and the 0.00 mark records this specific operating profit figure before depreciation and amortization.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%AA%D7%A4%D7%A2%D7%95%D7%9C%D7%99%20EBITDA&width=1200&height=400&colorIndex=0&v=mwbxec28.yq-7cu2wow&start=20220704&end=20261111&filename=GURU_Markets_-_ACRV_-_Acrivon-Therapeutics_-_Operating-profit-EBITDA "Acrivon - רווח לפני ריבית, מסים ופחת ACRV (תקופה 23.11.2025 - 11.11.2026) | 👁️GURU.Markets👁️")
פילוחי נתונים אנליטיים מרוכזים עבור Acrivon Therapeutics, Inc. (ACRV)
For Acrivon Therapeutics (ACRV), which invests accumulated cash into costly oncology research, the EBITDA_Co trend visualizes the dynamics of operating cash flow excluding depreciation and debt service. This indicator measures the business's actual ability to generate cash, allowing investors to assess the risk of capital freeze and the company's liquidity resilience amid macroeconomic pressure or recession.
